Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

August 10, 2025

Study Completion Date

August 10, 2025

Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
DRUG

Camrelizumab

2 cycles Camrelizumab before endoscopic surgery and one year after

DRUG

Chemotherapy

2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery

PROCEDURE

endoscopic surgery

standard endoscopic surgery for recurrent nasopharyngeal carcinoma

Trial Locations (7)

200031

RECRUITING

Eye& ENT Hospital, Fudan University, Shanghai

Unknown

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

NOT_YET_RECRUITING

Fujian Provincial Hospital, Fuzhou

NOT_YET_RECRUITING

Shenzhen Second People's Hospital, Shenzhen

NOT_YET_RECRUITING

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

NOT_YET_RECRUITING

Shanghai Zhongshan Hospital,Fudan University, Shanghai

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

lead

Eye & ENT Hospital of Fudan University

OTHER